The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
Table 2
Neoadjuvant chemotherapy characteristics of cases in this study.
Neoadjuvant chemotherapy characteristics
LAG
OG
value
N = 77 (%)
N = 76 (%)
Regimen of NACT
0.271
XELOX
70 (90.9)
63 (82.9)
FOLFOX
2 (2.6)
5 (6.6)
SOX
5 (6.5)
5 (6.6)
FLOT
0 (0.0)
3 (3.9)
Cycles completed
0.078
2 cycles
5 (6.5)
10 (13.2)
3 cycles
67 (87.0)
55 (72.4)
4 cycles
5 (6.5)
11 (14.5)
Clinical response per RECIST criteria
0.330
Complete response
5 (6.5)
2 (2.6)
Partial response
47 (61.0)
40 (52.6)
Stable disease
24 (31.2)
31 (40.8)
Progressive disease
1 (1.3)
3 (3.9)
Tumor downstage
0.336
Yes
59 (76.6)
53 (69.7)
No
18 (23.4)
23 (30.3)
Chemotherapy-surgery interval time (weeks)
6.3 ± 1.7
6.7 ± 2.0
0.327
Grade 2-4 adverse effects of NACT#
17 (22.1)
20 (26.3)
0.540
WBC decrease
12 (15.6)
13 (17.1)
0.799
Platelet decrease
10 (13.0)
11 (14.5)
0.789
Neutrophil decrease
13 (16.9)
14 (18.4)
0.803
Anemia
3 (3.9)
4 (5.3)
0.686
Hepatic dysfunction
1 (1.3)
5 (6.6)
0.116
Nausea or vomiting
1 (1.3)
2 (2.6)
0.620
Diarrhea
1 (1.3)
0 (0.0)
>0.999
Itching
2 (2.6)
3 (3.9)
0.681
Asitia
2 (2.6)
2 (2.6)
>0.999
Fatigue
1 (1.3)
3 (3.9)
0.363
Neurotoxic effect
1 (1.3)
0 (0.0)
>0.999
LAG: laparoscopy-assisted gastrectomy; OG: open gastrectomy; NACT: neoadjuvant chemotherapy; WBC: white blood cell. #Adverse effects were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE 4.0), and one patient can have more than 1 adverse effects.
